FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1499539085> ?p ?o ?g. }

• W1499539085 abstract "Transmucosal nasal drug delivery is a drug delivery option for challenging clinical situations where common drug administrations (e.g., intravenous, intramuscular, or oral) are inapplicable. For drugs with constricted oral bioavailability, due to degradation in the intestinal tract or hepatic first-pass metabolism, transmucosal nasal delivery is a convenient alternative to intravenous and intramuscular drug administration. The considerable blood flow, actually responsible for breath conditioning, benefits efficient systemic drug uptake and provides direct access to the systemic circulation for transmucosal absorbed drugs. Often, in nasal drug delivery the limited nasal capacity is disregarded and the instilled volumes exceed the limited capacity of the nose. Consequently, the administered preparations are partially swallowed and resulting pharmacokinetic characteristics refer to a combination of transmucosal nasal and gastrointestinal drug absorption. Due to low midazolam concentration, the commercially available preparations for intravenous administration (e.g. Dormicum , Roche) is inappropriate for transmucosal nasal midazolam delivery. For the optimization of transmucosal nasal midazolam delivery minimized administration volumes are essential to prevent swallowing of nasally administered preparations. Therefore, nasal preparations with enhanced midazolam concentrations need to be provided. In Project I different preparations for transmucosal nasal midazolam delivery were developed. The impact of vehicle and application modality on the pharmacokinetics of nasally applied midazolam was studied by administration of the developed preparations to healthy volunteers (Project II). The benefit of two nasal midazolam preparations for procedural anxiolysis in anxious patients undergoing MRI examinations was compared (Project III). Project I: Midazolam solubilization with RMβCD (randomized methylated-β-cyclodextrin, a cyclodextrin derivative) facilitated compounding of midazolam preparations adjusted to the limited volumetric capacity of the nose. RMβCD (added in equimolar or higher concentration to solubilize midazolam) reduced midazolam release in drug release studies with semi-permeable cellophane membranes (in vitro). Stability data affirmed shelf life of at leastmonths for RMβCD containing nasal midazolam preparations. Addition of chitosan hydrochloride (penetration enhancer) affected midazolam stability; therefore shelf life of the chitosan containing nasal midazolam preparation was reduced. The developed preparations for transmucosal nasal midazolam delivery were the basis to study the influence of the vehicle and the application modality on pharmacokinetics and systemic bioavailability of nasally applied midazolam (Project II).Project II: Pharmacokinetic characteristics following nasal application of 1 mg midazolam(Preparation 1, 2, and 3) and 3 mg midazolam (Preparation 4 and 5) were compared withpharmacokinetic characteristics of 1 mg i.v. administered midazolam (Dormicum®, Roche). Theimpact of RMbCD (solubilizer), chitosan hydrochloride (penetration enhancer) and the applicationmodality (one- versus two-sided nasal administration) was investigated in this open-label study withhealthy volunteers. Volunteers were asked to describe nasal midazolam administration and toclassify local irritation after nasal midazolam administration. Pharmacologic effects were assessedby computer-controlled self-adjusting reaction time test (CRTT, recording reaction time andinterstimulus interval) and visual analog scale (VAS). Blood samples were serially obtained until6 hours after midazolam administration. Serum concentrations of midazolam and two metabolites(a-hydroxymidazolam and 4-hydroxymidazolam) were quantified by liquid chromatography-massspectrometry (LC-MS). Non-compartment and two-compartment pharmacokinetic modeling wasperformed to estimate pharmacokinetic parameters. Bioequivalence testing was performedaccording to the requirements of EMEA (European Agency for the Evaluation of MedicinalProducts).Systemic bioavailability of nasally applied midazolam ranged from 78% (Preparation 5) to 93%(Preparation 2), differences of bioavailability were not significant. After nasal administration of 1 mgmidazolam by Preparation 1, 2, and 3 mean Cmax was, 28.1 ± 9.1 mg/l, 30.1 ± 6.6 mg/l and28.9 ± 5.4 mg/l, respectively. After nasal administration of 3 mg midazolam by Preparation 4 and 5Cmax was, 72.6 ± 18.2 mg/l, and 82.2 ± 15.8 mg/l, respectively. Following nasal midazolamadministration tmax was between 7.1 ± 0.6 minutes (Preparation 5) and 11.7 ± 2.4 minutes(Preparation 4). All tested nasal administration modalities to deliver 1 mg midazolam provedbioequivalence. For Preparation 4 and Preparation 5 bioequivalence was not confirmed. The serumconcentration time profiles of the midazolam metabolites (a-hydroxymidazolam and 4-hydroxymidazolam) demonstrated exclusive transmucosal absorption of nasally appliedmidazolam. Swallowing of nasally delivered preparations was prevented and hepatic first-passeffect successfully circumvented. Consequently, the assessed pharmacokinetic parameterscharacterized pure transmucosal nasal midazolam delivery.Neither RMbCD (equimolar to midazolam) nor application modality (one- or two-sided) changedabsorption kinetics of nasally administered midazolam, whereas chitosan hydrochloride promotedabsorption of nasally applied midazolam. Significant higher midazolam serum concentrations wereachieved faster. The outcome of the pharmacokinetic study emphasizes the decisive role ofminimized nasal application volume to prevent swallowing of nasally applied preparations and toprovide for exclusive transmucosal midazolam absorption.Project III: In this randomized multicenter trial with 110 anxious and/or claustrophobic patientsundergoing MRI examinations, two nasal preparations for low-dose midazolam delivery,Midazolam MD Nasal Spray 5 mg/ml (MD) and Midazolam UD Nasal Spray 1 mg (UD), werecompared. Nasal administration of 1 mg or 2 mg midazolam was provided before MRI examination.Within both groups anxiety reduction was significant, but there was no difference in anxietyreduction between the MD and UD group. Local irritation following administration of UD nasal spraywas slightly more intense than local irritation after administration of MD nasal spray.Nasal delivery of low-dose midazolam is a safe therapy to provide procedural anxiolysis in patientsundergoing MRI examinations. The two compared low-dose midazolam preparations fortransmucosal nasal delivery of midazolam proved therapeutic equivalence. Hence, anxious and/orclaustrophobic patients equally benefit from procedural anxiolysis during MRI examinationsfollowing administration of low-dose midazolam by MD nasal spray or UD nasal spray. Concerningconvenient handling, administration to laying patients, and hygienic aspects the new midazolamnasal spray (UD) is superior to the commonly used midazolam multidose nasal spray (MD).Overall, the presented nasal preparations facilitated characterization of exclusive transmucosalnasal absorbed midazolam. In vivo neither RMbCD (equimolar to midazolam) nor administrationmodality changed the pharmacokinetic profile of nasally applied midazolam. Chitosanhydrochloride promoted nasal midazolam absorption but clinical relevance (e.g., for the treatmentof status epilepticus) is to be verified in further clinical investigations. High systemic bioavailabilityof nasally applied midazolam demonstrated the veritable potential of transmucosal nasal drugdelivery as alternative to invasive drug administration." @default.
• W1499539085 created "2016-06-24" @default.
• W1499539085 creator A5049611579 @default.
• W1499539085 date "2008-01-01" @default.
• W1499539085 modified "2023-09-27" @default.
• W1499539085 title "Transmucosal nasal drug delivery : systemic bioavailability of nasally applied midazolam" @default.
• W1499539085 doi "https://doi.org/10.5451/unibas-004557994" @default.
• W1499539085 hasPublicationYear "2008" @default.
• W1499539085 type Work @default.
• W1499539085 sameAs 1499539085 @default.
• W1499539085 citedByCount "0" @default.
• W1499539085 crossrefType "dissertation" @default.
• W1499539085 hasAuthorship W1499539085A5049611579 @default.
• W1499539085 hasConcept C112705442 @default.
• W1499539085 hasConcept C178790620 @default.
• W1499539085 hasConcept C181389837 @default.
• W1499539085 hasConcept C185592680 @default.
• W1499539085 hasConcept C201253974 @default.
• W1499539085 hasConcept C2776093070 @default.
• W1499539085 hasConcept C2776814716 @default.
• W1499539085 hasConcept C2778000748 @default.
• W1499539085 hasConcept C2779820397 @default.
• W1499539085 hasConcept C2780035454 @default.
• W1499539085 hasConcept C2780973058 @default.
• W1499539085 hasConcept C42219234 @default.
• W1499539085 hasConcept C71924100 @default.
• W1499539085 hasConcept C85663871 @default.
• W1499539085 hasConcept C98274493 @default.
• W1499539085 hasConceptScore W1499539085C112705442 @default.
• W1499539085 hasConceptScore W1499539085C178790620 @default.
• W1499539085 hasConceptScore W1499539085C181389837 @default.
• W1499539085 hasConceptScore W1499539085C185592680 @default.
• W1499539085 hasConceptScore W1499539085C201253974 @default.
• W1499539085 hasConceptScore W1499539085C2776093070 @default.
• W1499539085 hasConceptScore W1499539085C2776814716 @default.
• W1499539085 hasConceptScore W1499539085C2778000748 @default.
• W1499539085 hasConceptScore W1499539085C2779820397 @default.
• W1499539085 hasConceptScore W1499539085C2780035454 @default.
• W1499539085 hasConceptScore W1499539085C2780973058 @default.
• W1499539085 hasConceptScore W1499539085C42219234 @default.
• W1499539085 hasConceptScore W1499539085C71924100 @default.
• W1499539085 hasConceptScore W1499539085C85663871 @default.
• W1499539085 hasConceptScore W1499539085C98274493 @default.
• W1499539085 hasLocation W14995390851 @default.
• W1499539085 hasOpenAccess W1499539085 @default.
• W1499539085 hasPrimaryLocation W14995390851 @default.
• W1499539085 hasRelatedWork W1981680778 @default.
• W1499539085 hasRelatedWork W2016476803 @default.
• W1499539085 hasRelatedWork W2061776351 @default.
• W1499539085 hasRelatedWork W2073457923 @default.
• W1499539085 hasRelatedWork W2090074038 @default.
• W1499539085 hasRelatedWork W2109703670 @default.
• W1499539085 hasRelatedWork W2127567409 @default.
• W1499539085 hasRelatedWork W2163856143 @default.
• W1499539085 hasRelatedWork W2168732876 @default.
• W1499539085 hasRelatedWork W2358699957 @default.
• W1499539085 hasRelatedWork W2548758651 @default.
• W1499539085 hasRelatedWork W2604576864 @default.
• W1499539085 hasRelatedWork W2616824126 @default.
• W1499539085 hasRelatedWork W2738004376 @default.
• W1499539085 hasRelatedWork W2938995280 @default.
• W1499539085 hasRelatedWork W2943103306 @default.
• W1499539085 hasRelatedWork W2950029022 @default.
• W1499539085 hasRelatedWork W3209139492 @default.
• W1499539085 hasRelatedWork W2706453861 @default.
• W1499539085 hasRelatedWork W2862735244 @default.
• W1499539085 isParatext "false" @default.
• W1499539085 isRetracted "false" @default.
• W1499539085 magId "1499539085" @default.
• W1499539085 workType "dissertation" @default.